BD Announces Appointment of William A. Kozy as Chief Operating Officer

    BD Announces Appointment of William A. Kozy as Chief Operating Officer

PR Newswire

FRANKLIN LAKES, N.J., Nov. 6, 2012

FRANKLIN LAKES, N.J., Nov. 6, 2012 /PRNewswire/ --BD (Becton, Dickinson and
Company) (NYSE: BDX), a leading global medical technology company, today
announced the appointment of William A. Kozy as Chief Operating Officer,
effective today. Mr. Kozy adds this title to his current title of Executive
Vice President. He will continue to report to Vincent A. Forlenza, Chairman,
Chief Executive Officer and President.

"Bill's new title reflects his leadership role and the additional
responsibilities that he has taken on over the last year, including oversight
of BD's three business segments and working with me to drive BD's growth and
innovation focus," said Mr. Forlenza.

Mr. Kozy, 60, joined BD in 1974 in a sales role in the BD Division selling
laboratory products. This focus on blood collection eventually led to his
first general management position as President of BD Vacutainer^® Systems. His
subsequent leadership positions include, among others, President, BD Worldwide
Injection Systems; Senior VP, Company Operations; President, BD Diagnostics;
and Executive Vice President.

Mr. Kozy has a B.A. cum laude in English from Kenyon College in Ohio.

About BD
BD is a leading global medical technology company that develops, manufactures
and sells medical devices, instrument systems and reagents. The Company is
dedicated to improving people's health throughout the world. BD is focused on
improving drug delivery, enhancing the quality and speed of diagnosing
infectious diseases and cancers, and advancing research, discovery and
production of new drugs and vaccines. BD's capabilities are instrumental in
combating many of the world's most pressing diseases. Founded in 1897 and
headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000
associates in more than 50 countries throughout the world. The Company serves
healthcare institutions, life science researchers, clinical laboratories, the
pharmaceutical industry and the general public. For more information, please

Colleen T. White, Corporate Communications – 201-847-5369;
Monique N. Dolecki, Investor Relations – 201-847-5378;

SOURCE BD (Becton, Dickinson and Company)

Press spacebar to pause and continue. Press esc to stop.